|
Market Closed –
|
|
|||
|
1.930 USD |
+6.04% |
3.305 |
+71.24% | |
April 16, 2025 at 07:38 am EDT
© MT Newswires – 2025
|
Top Premarket Gainers |
07:38am |
MT |
|
RadNet to Acquire iCad in $103 Million All-Stock Deal |
Apr. 15 |
MT |
|
RadNet, Inc. entered into an Agreement and Plan of Merger to acquire iCAD, Inc. for approximately $100 million. |
Apr. 14 |
CI |
|
ICAD, Inc. Appoints Mark Koeniguer as Chief Commercial Officer |
Apr. 08 |
CI |
|
ICAD, Inc., Q4 2024 Earnings Call, Mar 19, 2025 |
Mar. 19 |
|
|
ICAD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Mar. 19 |
CI |
|
ICAD, RamSoft Collaborate to Enhance Breast Cancer Detection |
Mar. 05 |
MT |
|
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025 |
Feb. 26 |
CI |
|
ICAD, Inc. Provides Earnings Guidance for the Fourth Quarter Ended December 31, 2024 |
Jan. 27 |
CI |
|
ICAD, Inc. Advances Fight Against Breast Cancer with FDA-Cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health At Rsna 2024 |
Dec. 04 |
CI |
|
ICAD, Inc., Q3 2024 Earnings Call, Nov 13, 2024 |
Nov. 13 |
|
|
Earnings Flash (ICAD) ICAD Reports Q3 Loss $-0.07 |
Nov. 13 |
MT |
|
Earnings Flash (ICAD) ICAD Posts Q3 Revenue $4.2M |
Nov. 13 |
MT |
|
ICAD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 13 |
CI |
|
ICAD, Inc.’s ProFound Detection Version 4.0 Gains FDA Clearance |
Nov. 12 |
CI |
|
ICAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024 |
24-10-03 |
CI |
|
Lexaria Bioscience Taps InVivo Therapeutics CFO Richard Christopher As New CEO |
24-09-05 |
MT |
|
ICAD, Inc., Q2 2024 Earnings Call, Aug 13, 2024 |
24-08-13 |
|
|
ICAD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-13 |
CI |
|
Earnings Flash (ICAD) ICAD Reports Q2 Revenue $5M, vs. Street Est of $4.4M |
24-08-13 |
MT |
|
Earnings Flash (ICAD) ICAD Reports Q2 Loss $-0.07, vs. Street Est of $-0.07 |
24-08-13 |
MT |
|
ICAD, Inc. and Windsong Radiology Announces Strategic Commercial Agreement to Implement AI-Powered Mammography |
24-07-29 |
CI |
|
ICAD, Inc. – Shareholder/Analyst Call |
24-06-13 |
|
|
ICAD, Inc., Q1 2024 Earnings Call, May 15, 2024 |
24-05-15 |
|
|
Earnings Flash (ICAD) ICAD Posts Q1 Revenue $5M, vs. Street Est of $4.4M |
24-05-15 |
MT |
ICAD: Dynamic Chart
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
More about the company
Buy
Average target price
4.750USD
Spread / Average Target
+146.11%
Consensus
